NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,410,000 | -55.0% | 2,644,600 | -43.1% | 0.02% | -59.1% |
| Q2 2020 | $3,133,000 | +17.3% | 4,644,600 | 0.0% | 0.04% | -2.2% |
| Q1 2020 | $2,671,000 | -56.4% | 4,644,600 | 0.0% | 0.04% | -48.9% |
| Q4 2019 | $6,131,000 | -34.0% | 4,644,600 | 0.0% | 0.09% | -50.0% |
| Q3 2019 | $9,289,000 | -17.7% | 4,644,600 | 0.0% | 0.18% | +0.6% |
| Q2 2019 | $11,286,000 | -0.4% | 4,644,600 | 0.0% | 0.18% | 0.0% |
| Q1 2019 | $11,333,000 | +67.1% | 4,644,600 | 0.0% | 0.18% | +40.0% |
| Q4 2018 | $6,781,000 | -45.9% | 4,644,600 | 0.0% | 0.12% | -17.2% |
| Q3 2018 | $12,540,000 | -8.1% | 4,644,600 | +18.5% | 0.15% | -7.4% |
| Q2 2018 | $13,640,000 | -30.8% | 3,919,600 | 0.0% | 0.16% | -33.2% |
| Q1 2018 | $19,716,000 | -15.9% | 3,919,600 | 0.0% | 0.24% | -17.6% |
| Q4 2017 | $23,439,000 | -27.0% | 3,919,600 | 0.0% | 0.30% | -3.6% |
| Q3 2017 | $32,102,000 | -21.8% | 3,919,600 | 0.0% | 0.31% | -28.8% |
| Q2 2017 | $41,077,000 | – | 3,919,600 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 4,256,526 | $11,493,000 | 2.10% |
| Vivo Capital, LLC | 6,619,190 | $17,872,000 | 1.80% |
| Novo Holdings A/S | 4,703,720 | $12,700,000 | 1.01% |
| Rock Springs Capital Management LP | 1,800,000 | $4,860,000 | 0.18% |
| Orbimed Advisors | 4,644,600 | $12,540,000 | 0.15% |
| Clear Harbor Asset Management, LLC | 212,500 | $443,000 | 0.09% |
| Granahan Investment Management | 247,276 | $668,000 | 0.04% |
| WEDBUSH SECURITIES INC | 92,050 | $249,000 | 0.03% |
| Laurion Capital Management LP | 419,670 | $1,133,000 | 0.01% |
| SECTORAL ASSET MANAGEMENT INC | 38,255 | $103,000 | 0.01% |